Table 1.

Possible antigen targets for CAR-T cells in AML.

Antigen	Expression on AML Leukemic Cells	Expression on LSCs	Expression on Healthy Hematopoietic Cells	References
CD33 Siglec-3	90–99%	+	myeloid progenitor cells, unipotent colony-forming cells, maturing granulocytes and monocytes	[25,26,27,28]
CD123 IL-3Rα	50–78%	+	low level/no expression on HSCs, monocytes, plasmoid dendritic cells, basophils	[29,30,31,32,33]
FLT3 CD135	54–92%	+	HSCs, myeloid progenitor cells	[24,34]
CLL-1	78–92%	+	granulocytes, monocytes and their progenitors	[35,36]

AML—acute myeloid leukemia, LSCs—leukemic stem cells, CD33 (Siglec-3)—sialic acid binding Ig-like lectin 3, CD123 (IL-3Rα)—α chain of the interleukin-3 receptor, FLT3 (CD135)—fms-like tyrosine kinase 3, CLL-1—C-type lectin-like molecule-1, “+”—the presence of expression on LSCs HSCs—hematopoietic stem cells.